Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Anti-human CCL24 monoclonal antibody · 2 trials · 2 indications
Number of subjects with treatment-emergent adverse events (any, related, serious, and severe) - Safety-related endpoint
Number of subjects with treatment-emergent adverse events (any, related, serious, and severe) - Safety-related endpoints
Observed maximum plasma concentration
Time to reach the observed maximum plasma concentration (Tmax)
Area under the curve (AUC) to the final concentration ≥ limit of quantitation (LOQ), AUC(0-t) and to infinity AUCinf
Elimination rate constant, determined by linear regression of the terminal points of the ln-linear plasma concentration-time curve
Terminal elimination half-life, defined as 0.693/λz
| Arm | Type | Description |
|---|---|---|
| Anti-human CCL24 monoclonal antibody (CM-101) | EXPERIMENTAL | Anti-human CCL24 monoclonal antibody CM-101 Intravenous Infusion over 60 minutes (±5 minutes) |
| Placebo | PLACEBO_COMPARATOR | Placebo - intravenous infusion |
| Name | Type | Description |
|---|---|---|
| Anti-human CCL24 monoclonal antibody (CM-101) | BIOLOGICAL | Anti-human CCL24 monoclonal antibody (CM-101) 100 mg Intravenous Infusion over 60 minutes (±5 minutes) |
| Placebo | OTHER | Placebo - intravenous infusion |
Inclusion Criteria: * Subjects with diagnosis of large duct PSC of more than 24 weeks' duration * Subjects that have no significant clinical concern for cholangiocarcinoma based on clinical, laboratory or imaging findings * Subjects with serum Alkaline phosphatase (ALP) greater than 1.5 × Upper lim...
Anti-human CCL24 monoclonal antibody, also known as CM-101, is being developed for Primary Sclerosing Cholangitis (PSC) and for medical conditions involving inflammatory and fibrotic mechanisms. It has been studied in healthy subjects and in patients with PSC. The drug is currently in clinical development and is not approved.
Anti-human CCL24 monoclonal antibody is developed by Chemomab Therapeutics Ltd., a biopharmaceutical company traded on the NASDAQ under the ticker CMMB. The company is conducting clinical trials of the drug for Primary Sclerosing Cholangitis and related inflammatory and fibrotic conditions.
Anti-human CCL24 monoclonal antibody is in clinical development. It has completed a Phase 1 trial in healthy subjects and a Phase 2 trial in patients with Primary Sclerosing Cholangitis. The drug is investigational and has not been approved by regulatory authorities.
Anti-human CCL24 monoclonal antibody has been studied in two completed trials. NCT04595825, the SPRING study, was a Phase 2 trial in 77 patients with Primary Sclerosing Cholangitis across the US, Germany, Israel, Spain, and the UK. NCT06025851 was a Phase 1 trial in 32 healthy male subjects in Israel.
Yes, Anti-human CCL24 monoclonal antibody is also known as CM-101. The drug is being developed by Chemomab Therapeutics under the name CM-101 in clinical trials for Primary Sclerosing Cholangitis and other inflammatory and fibrotic conditions.